ESKATA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eskata, and what generic alternatives are available?
Eskata is a drug marketed by Aclaris and is included in one NDA. There are five patents protecting this drug.
This drug has eighteen patent family members in sixteen countries.
The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.
DrugPatentWatch® Generic Entry Outlook for Eskata
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 21, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ESKATA?
- What are the global sales for ESKATA?
- What is Average Wholesale Price for ESKATA?
Summary for ESKATA
| International Patents: | 18 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 155 |
| Patent Applications: | 2,195 |
| What excipients (inactive ingredients) are in ESKATA? | ESKATA excipients list |
| DailyMed Link: | ESKATA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ESKATA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ESKATA
ESKATA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ESKATA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ESKATA
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ESKATA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ESKATA
When does loss-of-exclusivity occur for ESKATA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15249841
Patent: Peroxide formulations and methods and applicators for using the same
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2016024630
Patent: composição tópica, uso de uma composição tópica e aplicador
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 46568
Patent: FORMULES DE PEROXYDE ET PROCEDES ET APPLICATEURS POUR LEUR UTILISATION (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME)
Estimated Expiration: ⤷ Sign Up
China
Patent: 6659643
Patent: 过氧化物制剂及使用过氧化物制剂的方法和施加器 (Peroxide formulations and methods and applicators for using the same)
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 34061
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 34061
Patent: FORMULES DE PEROXYDE ET PROCÉDÉS ET APPLICATEURS POUR LEUR UTILISATION (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 8462
Patent: פורמולציות פראוקסיד ושיטות ויישומים לשימוש בהן (Peroxide formulations and methods and applicators for using the same)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 22217
Estimated Expiration: ⤷ Sign Up
Patent: 17513907
Patent: 過酸化物製剤ならびにその使用のための方法および塗布器
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 16013826
Patent: FORMULACIONES DE PEROXIDO Y METODOS Y APLICACIONES PARA UTILIZARLAS. (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME.)
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 34061
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 34061
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 11662
Patent: ПЕРОКСИДНЫЕ КОМПОЗИЦИИ И СПОСОБЫ И АППЛИКАТОРЫ ДЛЯ ИХ ПРИМЕНЕНИЯ (PEROXIDE COMPOSITIONS AND METHODS AND APPLICATORS FOR USE THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 16145236
Patent: ПЕРОКСИДНЫЕ КОМПОЗИЦИИ И СПОСОБЫ, И АППЛИКАТОРЫ ДЛЯ ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201608775X
Patent: PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 170029413
Patent: 과산화물 제제 및 이를 사용하기 위한 방법 및 어플리케이터 (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 28711
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ESKATA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3134061 | FORMULES DE PEROXYDE ET PROCÉDÉS ET APPLICATEURS POUR LEUR UTILISATION (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME) | ⤷ Sign Up |
| Austria | 397452 | ⤷ Sign Up | |
| New Zealand | 527673 | Composition comprising at least 23% hydrogen peroxide for removal of acrochordons, aka skin tags | ⤷ Sign Up |
| Denmark | 3134061 | ⤷ Sign Up | |
| Poland | 3134061 | ⤷ Sign Up | |
| Brazil | 112016024630 | composição tópica, uso de uma composição tópica e aplicador | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ESKATA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3106463 | 122020000012 | Germany | ⤷ Sign Up | PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
| 3106463 | CA 2020 00013 | Denmark | ⤷ Sign Up | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
| 0302769 | 98C0036 | Belgium | ⤷ Sign Up | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 |
| 2787345 | CR 2016 00055 | Denmark | ⤷ Sign Up | PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531 |
| 0281459 | 98C0036 | France | ⤷ Sign Up | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 |
| 2523731 | 24/2020 | Austria | ⤷ Sign Up | PRODUCT NAME: OSILODROSTAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 (MITTEILUNG) 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
